Human Papillomavirus (HPV), minireview and collateral expected benefits of the vaccine. by Mendieta Zerón, Hugo et al.
4
4 NJOG / VOL. 8/ NO. 1 / ISSUE 15/ Jan-Jun, 2013
NJOG 2013 Jan-Jun;8(1):4-9 REVIEW ARTICLE
CorrespondenCe
Dr Hugo Mendieta Zerón




Human Papillomavirus: Minireview and Collateral 
Expected Benefits of the Vaccine
mendieta Z, lópez H, layton t, santillán B, Colín f, Camarillo r, domínguez g
Molecular Biology Laboratory, Medical Research Center (CICMED), Autonomous University of the State of Mexico 
(UAEMex), Toluca, Mexico.
Cervical neoplasia is the second leading cause of neoplastic death in Latin America. It is generally accepted that all cervical carcinomas 
have at least one high risk Human Papillomavirus (HPV). Due to the causal relationship of specific HPV types and cervical cancer and 
its role as precursor of skin lesions it is important to identify the involved genotype. HPV, as other tumor-viruses, induces oncogenesis by 
manipulating an array of different cellular pathways, which leads to immortalization and proliferation of the infected cells by disrupting the 
mitotic checkpoint upon infection of the host cell. Actually the role of the immune response in the development of cervical cancer is unknown 
as is the relationship between the type and level of expression of messenger RNA (mRNA) of interferon gamma (IFN-γ), transforming 
growth factor beta 1 (TGF-β1) and interleukin (IL)-4 in the cervical microenvironment within each of the stages of carcinogenesis with the 
HPV genotype causing the infection. An average annual cost to treat cervical cancer is U.S. $ 10,283 per patient. Taking into account the 
World Population Prospects: The 2010 Revision, in ten years the accumulated cases of cervical cancer might be 3,286,534, thus making 
a total budget of U.S. $ 33,795.4 million to treat all women. Universal vaccination against HPV might result in extended benefits as the 
decrease in mouth and oropharynx cancers as well as the reduction in health cost for the attendance of several neoplasias.
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INTROduCTION
Human Papillomavirus (HPV) infection is high in several 
countries, being described until now more than 100 
genotypes, classified into species from genus α or β; most 
of them causing clinically imperceptible infections and if 
perceptible, most will appear as skin papilloma or mucosal 
papilloma (warts).1,2 Besides these lesions HPV infection 
is associated with several types of anogenitaltumors, 
particularly cervical carcinoma. Fortunately, less than 5% 
of women infected with HPV will develop cervico-uterine 
cancer.3
In Mexico, cervical carcinoma is the second leading cause 
of mortality among women older than 25 years. The 
Mexican National Health System offers medical attention 
to about 9,000 cases of cervicouterine cancer and 4,000 
deaths are registered annually.4 In women examined with 
the Papanicolaou cervical test in the city of Durango, 
Mexico, a 48% prevalence of HPV infection was found, 
being genotype 16 the most common in that survey.5 In 
men, HPV prevalence in the genital tract tends to be similar 
to that in women with a prevalence in external genitalia of 
46.4%, 20.8% in the urethra and 12.1% in the meatus.6
It is generally accepted that all cervical carcinomas have 
at least one high risk HPV.7 Moreover, genotypes 16 and 
18 are found in approximately 70% of the cases.8, 9 From 
all currently identified genotypes, more than 40 infect 
the genital tract, from which 15-20 (genotypes 16, 18, 26, 
31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82) 
have been associated with cervical cancer or high-grade 
of cervical intraepitelialneoplasia (CIN) and for this reason 
are classified as high risk types.5,7 On the contrary, some 
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HPV genotypes (6, 11, 40, 42, 43,44, 54, 61, 70, 72, 81) are 
classified as low risk types.9 Due to the causal relationship 
of specific HPV types and cervical cancer and its role as 
precursor of skin lesions it is important to identify the 
involved genotype.8
HPV types and associated diseases
HPV is a non enveloped double stranded DNA virus, with 
around 8000 base pairs divided into early region (E), late 
region (L) and control region. HPV has 8 open reading 
frames (ORFs) in one chain. The initial ORF encodes 
structural proteins. There is a central region (1 kb in length) 
called upstream regulatory region (toward the 5 'end) 
between the initial and final ORF that may determine the 
HPV specificity for a given tissue. There are also internal 
transcription signals, both, activators and inhibitors, which 
can act as cis elements of action by binding cellular and 
viral proteins that transregulate viral genome function. 
Types are identified when they show more than a 10% 
difference between their E6, E7 y L1genetic sequences. 
A subtype or variant reaches only 2-5% of genetic 
differences.10HPV 16 is the most frequent genotype in the 
world, except in Indonesia and Algeria where genotype 
18 is more frequent. Africa and Latin America have a high 
prevalence of the oncogenic types 16, 18, 31, 33, 35, 45, 
51, 52, 58, 59. In Western Africa, HPV 45 is present with 
high frequency. In Central America and South America 
types 33, 39 and 59 are highly frequent.10
There are 30-40 genital HPV types that cause venereal 
infections that are highly and commonly contagious, 
showing 26.8% prevalence in USA women ages 24 to 59 
years old. Women in Mexico demonstrate around a 14% 
prevalence rate. Most of these infections are not clinically 
manifested, others are detected as vulvar, vaginal, cervical 
or penile papilloma, and some others appear as warts. 
Cluster forms are common for HPV types 6 and 11 and less 
common for HPV 16 types. Intraepithelial lesion is more 
commonly present on 16, 18, 31, 6 and 11 types. HPV 16 
is observed in oral warts.10 Types 16 and 18 cause 70% of 
cervical neoplasia worldwide.11
Types 16 and 18 had been detected in vulvar, vaginal, 
penile, perianal and anal region neoplasias. They are 
also present in superior respiratory tract and esophagus 
neoplasias. HPV 33 is present in 44% of the cases of mama 
ductal invasive cancer. Urethral and prostatic cancer show 
types 16 and 18 being involved.11
Transmission
Transmission is by direct contact with infected skin, 
mucosal or sexual fluids, mainly by sexual act with 
penetration. This is the most frequent sexually transmitted 
disease, in fact, 50% of sexually active individuals are 
considered infected at some time in their lives.10 The risk 
of vertical transmission of HPV genotypes is relatively low 
although, children of mothers' who are HPV-positive at 
the post-partum visit are about 5 times more likely to test 
HPV-positive than children of corresponding HPV-negative 
mothers.12
Prevalence of HPV infection rises annually in women 14 to 
24 years old and gradually declines at 59 years old.11,13Even 
though prevalence is higher in men, HPV causes more 
damage in women.14 Prevalence is higher in prostitutes.15It 
rises with a higher number of sexual partners and with 
early start of sexual activity. 
The infection can be of only one type, or may involve many 
types. Likewise, it may pass several years before developing 
cancer or pre-malignant lesions, however, a minor part of 
detected precancer lesions evolve to cancer.16
Pathogenicity
HPV gene expression is polycistronic initiating from multiple 
promoters. Gene regulation occurs at transcriptional, 
but particularly post-transcriptional levels, including RNA 
processing, nuclear export, mRNA stability and translation. 
A close association between the virus replication cycle and 
epithelial differentiation adds a further layer of complexity. 
HPV infected cells can be cleared by apoptotic pathways 
or they may persist in a chronic infection state that 
can develop neoplasia. As with other oncovirus, HPV 
develops oncogenesis by manipulation in arrangement on 
different cellular pathways that lead to immortalization 
and proliferation of infected cells by altering mitosis 
checkpoints often complemented by functional inhibition 
or proteosome degradation of many tumor suppressor 
proteins by products of viral genetic code.17Genetic 
regulations take place at the transcriptional level and 
with particularity on a post-transcriptional level that 
includes RNA process, nuclear exportation, mRNA stability 
and translation. It follows a complex level of association 
between viral replication and epithelial differentiation.18
HPV oncogenic high risk types succeed in integrating to 
the hostess cells the viral genoma.10 Thirty percent of 
type 16 cervical cancer uses an episomal way ends up on: 
production and activation of E6 and E7 proteins. Another 
significant difference between low and high oncogenic 
type risk is the affinity of E6 and E7 to the p53 and 
retinoblastoma (pRB) proteins.10Additionally, oncogenic 
HPV types code for an E5 protein involved in carcinogenic 
transformation and immune evasion, while many non 
oncogenic types lack an ORF for E5 or lacks a start codon 
for it.2
HPV as other tumor-viruses induce oncogenesis through 
manipulating an array of different cellular pathways, which 
lead to immortalization and proliferation of the infected 
cells by disrupting the mitotic checkpoint upon infection 
of the host cell. This is often accomplished by functional 
inhibition or proteasomal degradation of many tumor 
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suppressor proteins by virally encoded gene products. 
The virally infected cells can either be eliminated via 
cell-mediated apoptosis or persist in a state of chronic 
infection. Importantly, the chronic persistence of infection 
by tumor viruses can lead to oncogenesis.17 In this regard; 
the most important involved proteins are E1, E2, E6, E7 and 
E1-E4.18-25
Immunology
HPV is considered an important factor in the origin and 
evolution of pre-malignant lesions of cervicouterine 
cancer, however, exposure to the virus is necessary but not 
sufficient to cause CIN.26 Fortunately, in 90% of the cases 
HPV can be cleared by the immune system in about two 
years.11,13-15,27
Scott et al. found that the pattern of Th1 immune response 
through the expression of interferon gamma (IFN-γ) and 
interleukin (IL)-2 is associated with the presence of HPV in 
cervical tissue.28 Al-Saleh et al. showed that CIN progression 
to cancer was associated to an immunoregulatory Th2 
response (IL-4 and 6).29 Wu et al. showed that tumor 
necrosis factor alpha (TNF-α) in addition to IL-2 and IFN-γ 
play a critical role in regulating the susceptibility of cervical 
keratinocytes to HPV infection in patients with CIN 2 and 
3.30 Th1 immune response is predominant in premalignant 
lesions, with or without HPV, being the IFN-γ expression 
related to the severity of the premalignant lesions. 
Viral infections are eliminated by the cellular immune 
response (CIR) that consists of the recognition and lysis 
of infected cells by T lymphocytes (LT) CD8+, an event 
promoted by IFN-γ secreted by the cells, also by the 
Natural killer cells (NK) and Th1 subpopulation of LT 
CD4+.31 There are however two known subpopulations 
named Th2 and Th3 that secrete IL-4 and transforming 
growth factor beta 1 (TGF-β1), respectively.32 Among the 
main functions of IL-4 and TGF-β is the CIR inhibition and 
another function of IL-4 is to activate the humoral immune 
response (HIR), however, activation of the HIR may allow 
progression of tumors caused by virus, therefore, the type 
and level of cytokine expression determines the course of 
the immune response and the outcome of viral infection 
and carcinogenesis. 
In low grade squamous intrepithelial lesion (LGSIL) and 
high grade squamous intrepithelial lesion (HGSIL) the CIR 
alteration is a favorable factor for progression to cervical 
cancer as has been demonstrated in HIV-coinfected 
patients.33 Actually the role of the immune response in 
the cervical cancer development and the relationship 
between the type and level of expression of messenger 
RNA (mRNA) of IFN- γ, TGF-β 1 and IL-4 in the cervical 
microenvironment within the stages of carcinogenesis or 
with the HPV genotype causing the infection is unknown.
Diagnosis, prevention and treatment
Diagnosis requires gynecological medical examination 
that includes Papanicolaou, colposcopy (Figure 1) and 
histopathological techniques. Even though expensive, 
genetic molecular techniques like polymerase chain 
reaction (PCR) and hybridization have been added to 
identify the virus. 
Figure 1. Low grade HPV genital infection (Colposcopic 
image). F1) euthrophic cervix, positive for acetone, easy 
bleeding and epithelial erosion with bacterial vaginosis, 
F2) exocervical visualization with acetic acid 3%, F3) 
visualization of increased vascularization, F4) Schiller test. 
Since 2006 there have been vaccines approved by the Food 
and Drug Administration (FDA), the Advisory Committee 
on Immunization Practices (ACIP), and the Center for 
Disease Control and Prevention (CDC) and by the World 
Health Organization (WHO). 
The quadrivalent vaccine, Gardasil® (HPV4), protects 
against infection with HPV types 6, 11, 16 and 18. This 
vaccine has demonstrated its effectiveness in preventing 
cervical, vaginal, vulvar and anal cancers as well as genital 
warts in both genders. The second HPV vaccine, Cervarix® 
(HPV2), is a bivalent vaccine that provides protection 
against HPV types −16 and −18. It is recommended in girls 
younger than 13 years. 
Actually there is no official treatment for HPV infection. 
Papilloma lesions can be remissible by the individual’s 
immune system and defence mechanisms. Many therapies 
are available for the treatment of HPV-associated disease, 
particularly external genital warts. However, at present, 
these therapies are for removing the lesion rather than 
specifically target HPV infection.25,34 Understanding mRNA 
and its regulation on HPV infection related diseases will 
give clues to develop diagnosis techniques and antiviral 
therapy.18 Future direct or indirect therapies will include 
the following: antiviral drugs against HPV functional 
proteins; increase immune system ability to solve the 
infection, apoptosis induction on HPV infected cells;34 or 
small interference RNA (sRNAi) to target and inhibit viral 
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oncogenes in tumoral cells.35
Some advances on treatment research for HPV infection 
are based on: 1) curcumin treatment that inhibits HPV 16 
transcription of E6/E7 and restores expression of the tumor 
suppressor proteins p53, retinoblastoma and PTPN13,36 
2) proteasome inhibitors on HPV infected cervical cancer 
cells,37,38 3) development of a biphasic vesicles delivery 
system that injects IFN-α.39Future therapies will be 
directly or indirectly antiviral, targeting HPV protein 
functions or enhancing the ability of the immune system 
to resolve infection or inducing apoptosis indirectly in HPV-
infected cells.34
Cervical cancer treatment depends on the stage and 
dissemination at the moment of diagnosis; options are 
surgery (hysterectomy), radiotherapy and chemotherapy.25
Collateral benefits of HPV vaccine
Cancer of the cervix is one of the most important neoplasias, 
with an estimated worldwide incidence of about half 
a million cases per year and 260,000 deaths around the 
world in 2005, of which 80% occurred in developing 
countries.40 In Brazil, the annual cost per patient with 
cervical cancer is, approximately, U.S. $4,970.00,41 while in 
Tunisia it is U.S. $ 3,180.00.42,43 In some countries, the direct 
cost per case of cervical cancer reaches higher values, as in 
Belgium U.S. $ 12,434.00, USA U.S. $ 18,799.00, the United 
Kingdom U.S. $ 8,810.00 and France U.S. $ 13,505.00.44-47 
An average annual cost with the previous information is 
U.S. $ 10,283 per patient. Taking into account the World 
Population Prospects: The 2010 Revision,48 in ten years, the 
accumulated cases of cervical cancer might be 3,286,534, 
thus making a total budget of U.S. $ 33,795.4 million.13 to 
treat all women. Of course this will not occur and the real 
expenditure will be much lower.
For the WHO, a 80% coverage of Pap screening among 
women 25 to 59 years would be enough to impact the 
morbidity and mortality indicators, which can be observed 
after four years of implementation of early detection 
actions.49
HPV also causes an estimated ~30,000 oropharyngeal 
cancers, worldwide.50 In fact, HPV is now the major cause 
of oropharyngeal cancer in developed countries, detected 
in 45–90% of cases.51 HPV has also been detected in a 
smaller subset of laryngeal (24%) and oral cavity (23%) 
cancers.50
Recent data demonstrate that HPV also plays a role in head 
and neck cancers, and non-cancerous conditions such as 
recurrent respiratory papillomatosis. As more and more 
information about the role of infection in non-cervical 
diseases is amassed, additional questions about whether 
prophylactic HPV vaccines will effectively prevent these 
conditions are raised. 
It is possible that with the massive vaccination against 
HPV, other pathologies besides cervical cancer will be 
diminished in incidence. For example, according to the 
WHO, within all its members, the approximate number 
of deaths by mouth and oropharynx cancers were of 
281,500 (April 2011).52 Taking into account a constant 
ratio for mouth and oropharynx cancers of 3.9% of the 
worldwide population, with 45% of these malignancies 
associated to HPV and thinking positive with a hypothetical 
universal vaccination program against HPV, beginning with 
a coverage of 30%, a decrease of 253,063 cases would be 
accumulated in ten years.
CONCluSIONS
The role of the immune response in the cervical cancer 
development has not been explained successfully until now. 
As the knowledge of this system grows, new therapeutical 
options are designed. Universal vaccination against HPV 
might result in extended benefits as the decrease in mouth 
and oropharynx cancers as well as the reduction in health 
cost for the attendance of several neoplasias.
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